Asthma Inc — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$17,286	1
2021	Research	$36,298	3
2020	Research	$16,803	1
2019	Research	$288	1

Breakdown

Who paid Research payments · program years 2019–2023

AstraZeneca Pharmaceuticals LP $43,906 2 payments
AstraZeneca UK Limited $17,286 1 payment
GlaxoSmithKline, LLC. $9,195 2 payments
Novartis Pharmaceuticals Corporation $288 1 payment

Studies the money was for Research payments · program years 2019–2023

A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy $43,906 2 payments
A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome $17,286 1 payment
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $9,195 2 payments
A 26 Week Randomized Double Blind Placebo Controlled Multi Center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma $288 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.